Drug reference

Cabozantinib

Tyrosine Kinase Inhibitor · Antineoplastic agent

Tyrosine Kinase InhibitorAntineoplastic agent

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

FDA category + note

Top interactionssee all 12 →

AbarelixSevereDatabaseDDInter
AbciximabSevereDatabaseDDInter
AbirateroneSevereDatabaseDDInter
AcalabrutinibSevereDatabaseDDInter

Mechanism

Cabozantinib is an inhibitor of several protein kinases. It functions as a multikinase inhibitor, targeting pathways involved in cancer cell growth and progression.

Indications

Treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinomaAdvanced renal cell carcinomaHepatocellular cancer (HCC) in the second-line setting (for patients with good performance status and intact liver function)systemic therapy of medullary thyroid cancer without regard to driver mutation statusadvanced RCC (as monotherapy and in combination with nivolumab)HCC who have been previously treated with sorafenibprogressive, metastatic medullary thyroid cancer

Dosing

Adult: For medullary thyroid carcinoma: 140 mg once daily by mouth using capsules. For advanced renal cell carcinoma: 60 mg once daily by mouth using tablets. For dose adjustment or treatment interruption due to side-effects, consult product literature (closely monitor for first 8 weeks of therapy). Note: Cabozantinib tablets and capsules are not bioequivalent.
Hepatic adjustment: The dose of cabozantinib should be reduced in patients with mild-to-moderate hepatic impairment.

Pharmacokinetics

Half-life

about 99 h (elimination)

Metabolism

CYP3A4 (substrate)

Contraindications

patients with a recent history of bleeding
patients with thromboembolic events

Side effects

Common

Palmar-plantar erythrodysaesthesia syndromediarrhea (≥25%)fatigue (≥25%)nausea (≥25%)PPES (≥25%)hypertension (≥25%)vomiting (≥25%)weight loss (≥25%)constipation (≥25%)

Serious